As of 2026-03-16, the Relative Valuation of Cytokinetics Inc (CYTK) is (156.02) USD. This relative valuation is based on P/E multiples. With the latest stock price at 60.06 USD, the upside of Cytokinetics Inc based on Relative Valuation is -359.8%.
The range of the Relative Valuation is (141.25) - (179.00) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.0x - 29.2x | 25.6x |
| Forward P/E multiples | 21.9x - 27.9x | 23.0x |
| Fair Price | (141.25) - (179.00) | (156.02) |
| Upside | -335.2% - -398.0% | -359.8% |
| Date | P/E |
| 2026-03-13 | -9.35 |
| 2026-03-12 | -9.35 |
| 2026-03-11 | -9.91 |
| 2026-03-10 | -10.00 |
| 2026-03-09 | -9.72 |
| 2026-03-06 | -9.41 |
| 2026-03-05 | -9.69 |
| 2026-03-04 | -9.70 |
| 2026-03-03 | -9.46 |
| 2026-03-02 | -9.57 |
| 2026-02-27 | -9.69 |
| 2026-02-26 | -9.75 |
| 2026-02-25 | -9.80 |
| 2026-02-24 | -10.92 |
| 2026-02-23 | -10.63 |
| 2026-02-20 | -10.58 |
| 2026-02-19 | -10.56 |
| 2026-02-18 | -10.43 |
| 2026-02-17 | -10.38 |
| 2026-02-13 | -10.32 |
| 2026-02-12 | -10.13 |
| 2026-02-11 | -10.40 |
| 2026-02-10 | -10.10 |
| 2026-02-09 | -9.87 |
| 2026-02-06 | -9.71 |
| 2026-02-05 | -9.38 |
| 2026-02-04 | -9.89 |
| 2026-02-03 | -10.08 |
| 2026-02-02 | -10.15 |
| 2026-01-30 | -9.84 |
| 2026-01-29 | -10.22 |
| 2026-01-28 | -10.15 |
| 2026-01-27 | -9.97 |
| 2026-01-26 | -9.84 |
| 2026-01-23 | -9.88 |
| 2026-01-22 | -10.11 |
| 2026-01-21 | -9.82 |
| 2026-01-20 | -9.93 |
| 2026-01-16 | -9.75 |
| 2026-01-15 | -9.88 |
| 2026-01-14 | -10.06 |
| 2026-01-13 | -9.86 |
| 2026-01-12 | -10.07 |
| 2026-01-09 | -9.74 |
| 2026-01-08 | -9.86 |
| 2026-01-07 | -10.19 |
| 2026-01-06 | -10.06 |
| 2026-01-05 | -9.54 |
| 2026-01-02 | -9.61 |
| 2025-12-31 | -9.90 |